BIYKEM BOZKURT to Angiotensin Receptor Antagonists
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Angiotensin Receptor Antagonists.
Connection Strength
2.044
-
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail. 2020 05; 26(5):370.
Score: 0.647
-
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Curr Cardiol Rep. 2018 04 17; 20(6):39.
Score: 0.562
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
Score: 0.201
-
Heart?Failure Drug Treatment-Inertia,?Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 01; 11(1):1-14.
Score: 0.191
-
Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. Ann Pharmacother. 2021 06; 55(6):805-813.
Score: 0.167
-
Update in recent clinical trials in heart failure. Curr Opin Cardiol. 2019 07; 34(4):307-314.
Score: 0.153
-
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol. 2009 Jul 15; 104(2):270-5.
Score: 0.077
-
The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022 Feb 03; 43(5):367-376.
Score: 0.046